Congratulations to the following individuals for obtaining extramural funding from
federal, state, and/or independent sources between February 1, 2021 - April 30, 2021!
NOTE: If any information has been inadvertently omitted, please contact the editor
(dflock@lsuhsc.edu) and a correction will be printed in the next issue of The Pulse.
National Institutes of Health (R21):
Jeffrey Gidday, PhD (Department of Ophthalmology)
“Reducing Vascular Cognitive Impairment Within and Across Generations by Epigenetic
Conditioning”
Imran Mungrue, PhD (Neuroscience Center of Excellence)
“Proof of principle for a Scalable Multiplex Proteome Quantitation Technology”
National Institutes of Health (R03):
Ping Wang, PhD (Department of Microbiology, Immunology and Parasitology)
“Isolation of Mononuclear Propagules from Coenocytic Hyphae of the Mucormycosis Pathogen
Rhizopus Delemar”
National Institutes of Health (F30):
Nathan Michael Sharfman, (Department of Physiology)
“Amygdala Modulation of Adolescent Alcohol Effects on Pain”
National Cancer Institute
Lucio Miele, MD, PhD (Department of Genetics) (Co-PI with Brigham and Women's Hospital)
“Comprehensive Molecular Characterization of Endometrial Cancer, Etiologic Heterogeneity,
and Racial Disparities”
National Science Foundation
Fern Tsien, PhD (Department of Genetics)
“Research Experience for Undergraduates in Genomics and Biochemistry”
Pharmaceutical and Company Grants:
Yussef Bennani, MD (Department of Medicine)
PPD/GSK
“A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting
Cabotegravir Plus Long-acting Rilpivirine from a Bictegravir Single Tablet Regimen
in HIV-1 Infected Adults who are Virologically Suppressed”
Michael Hagensee, MD, PhD (Departments of Medicine and Microbiology, Immunology and
Parasitology)
PPD Development
“Adaptive Platform Treatment Trial for Patients with COVID-19 (Adapt Out COVID) ACTIV-2
A5401 AZD7442”
Michael Hagensee, MD, PhD (Departments of Medicine and Microbiology, Immunology and
Parasitology)
PPD Development
“Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)
ACTIV-2 A5401 Camostat”
Frank Lau, MD (Department of Surgery)
Cytokind, Inc.
“Cytokind Adaptive Photo-Protection Trial Protocol TPL 0001”
Rebecca Lillis, MD (Department of Medicine, Section of Infectious Diseases)
Cepheid
“Clinical Evaluation of the Xpert Xpress Test”
Hollis O'Neal, Jr., M.D. (Department of Pulmonary Medicine, Our Lady of the Lake)
CytoVale, Inc.
“Collection of Normal Healthy Donor Blood Samples”
Stephanie Taylor, M.D. (Department of Microbiology, Immunology and Parasitology)
Becton Dickinson Corp
“Clinical performance of the BD Vaginal Panel for BD COR System as Compared to the
BD Vaginal Panel for BD MAX System”
Gabriel Tender, MD (Department of Neurosurgery)
Providence Medical Technology Corp
“CLN-PMT 129 Safety and Effectiveness of Posterior Cervical Stabilization System as
an Adjunct to Posterior Cervical Fusion, when Used in Combination with ACDF in Treatment
of Multi-level Cervical Degenerative Diseases or ‘FUSE'”